Meeting
2018 ASCO Annual Meeting
Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).
Authors
Wolfgang Janni
University of Ulm, Ulm, Germany
Wolfgang Janni , Ulrike Nitz , Brigitte Kathrin Rack , Oleg Gluz , Andreas Schneeweiss , Ronald E. Kates , Tanja N. Fehm , Hans Heinrich Kreipe , Sherko Kummel , Rachel Wuerstlein , Andreas D. Hartkopf , Michael Clemens , Toralf Reimer , Thomas W. P. Friedl , Lothar Haeberle , Peter A. Fasching , Nadia Harbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 522)
DOI
10.1200/JCO.2018.36.15_suppl.522
Abstract #
522
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata
Poster
2019 ASCO Annual Meeting
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
First Author: Theodoros Foukakis
Poster
2018 ASCO Annual Meeting
Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial.
First Author: Jose Bines
Poster
2014 ASCO Annual Meeting
A multicenter randomized study comparing 6 versus 12 months of trastuzumab in combination with dose-dense docetaxel following FEC as adjuvant treatment of women with axillary-node–positive or high-risk, node-negative breast cancer overexpressing HER2.
First Author: Dimitrios Mavroudis